Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
IMMX
IMMX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IMMX News
Immix Biopharma Closes $140.65 Million Offering of 16.78 Million Shares
May 22 2026
Newsfilter
Immix Biopharma Prices Public Offering at $8.94 per Share
May 21 2026
seekingalpha
Immix Biopharma Achieves 95% CR in NXC-201 Trial
May 21 2026
NASDAQ.COM
Immix Biopharma Reports Promising NXC-201 Trial Data in AL Amyloidosis
May 21 2026
seekingalpha
Immix Biopharma Prices $150 Million Underwritten Offering
May 21 2026
Newsfilter
Immix Biopharma Initiated with Overweight Rating by Morgan Stanley
Mar 25 2026
seekingalpha
Latest Rating Changes on Wall Street
Mar 25 2026
CNBC
Wall Street Analysts Adjust Ratings
Mar 09 2026
Benzinga
Wall Street Analysts Adjust Ratings
Mar 09 2026
Benzinga
Wall Street Analysts Adjust Ratings on Key Stocks
Mar 09 2026
Benzinga
NXC-201 Receives FDA Breakthrough Therapy Designation
Jan 28 2026
Newsfilter
Healthcare Stocks Surge in After-Hours Trading
Jan 28 2026
NASDAQ.COM
Immix Biopharma Files $750 Million Shelf Registration for Stock Offerings
Jan 12 2026
Benzinga
ImmixBio Closes 19.1M Share Offering, Netting $93.7M
Dec 09 2025
Globenewswire
ImmixBio Closes 19.1M Share Offering, Netting $93.7M
Dec 09 2025
Newsfilter
Immix Rises Following NXC-201 Results in Relapsed/Refractory AL Amyloidosis; BLA Expected in 2026
Dec 08 2025
NASDAQ.COM
Show More News
